Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 3Brain Neoplasms 3Medulloblastoma 2Glioblastoma 2Recurrence 1Gliosarcoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Temozolomide 30Radiotherapy 21Etoposide 9Carboplatin 9Bevacizumab 9Cyclophosphamide 8Vincristine 7Radiation 7Filgrastim 7Cisplatin 7Magnetic Resonance Spectroscopy 6Irinotecan 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5etoposide phosphate 4X-Rays 4Specimen Handling 4Phantoms, Imaging 4Lomustine 4Everolimus 4selpercatinib 3larotrectinib 3Thalidomide 3Paclitaxel 3Nuclear Medicine Department, Hospital 3Methotrexate 3Erlotinib Hydrochloride 3Chemotherapy, Adjuvant 3Celecoxib 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Central Nervous System Neoplasms × TPI-287 × Clear all
NCT01582152 2019-06-05

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 7 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡